David Chang, Allogene CEO (Jeff Rumans)

Al­lo­gene hit with FDA clin­i­cal hold af­ter a pa­tient ex­pe­ri­ences 'ab­nor­mal­i­ty' in CAR-T cells — shares ham­mered

The FDA has slapped a clin­i­cal hold on Al­lo­gene’s clin­i­cal tri­als af­ter a pa­tient in one of their ear­ly-stage stud­ies for the off-the-shelf cell ther­a­py …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.